About Us
Hunan Zhongsheng Quanpeptide Biotechnology Co., Ltd.
Zonsen PepLib Biotech Inc. is an innovative biotechnology company dedicated to the discovery and development of novel peptide-based therapeutics aimed at improving treatment options for patients worldwide. Founded in September 2017, PepLib is headquartered in Zhuzhou, China, with operations in Changsha, China, and a subsidiary in New Jersey, USA. PepLib employs more than 200 people, over 80% of whom are engaged in research and development.
PepLib closed its Series A financing round of CNY 100 million in December 2019, followed by a Series A+ financing round of CNY 220 million in April 2021. Most recently, the company secured nearly CNY 100 million through its Series B financing round in July 2025.
To date, PepLib has secured research and development (R&D) collaboration agreements with leading pharmaceutical enterprises, including Novartis, Lilly, AstraZeneca, Jiudian Pharmaceutical, and Kanion Pharmaceutical, among others.
PepLib has established a robust and diverse suite of proprietary peptide libraries and discovery capabilities, with a primary therapeutic focus in oncology and cardiometabolic diseases. PepLib’s platforms support multiple peptide-based modalities, including peptide radionuclide conjugates (PRCs), peptide oligonucleotide conjugates (POCs), and peptide drug conjugates (PDCs).
R&D investment
Since its establishment, the company has invested a cumulative total of approximately RMB 380 million in R&D. Over the next three years, it plans to allocate an additional RMB 600 million to R&D.
Achieve “dual‑engine” growth by: providing new‑drug R&D services based on our proprietary, cutting‑edge platform, coupled with an in‑house innovative drug pipeline.
R&D investment
Since its establishment, the company has cumulatively invested approximately RMB 265 million in R&D. Over the next three years, it plans to allocate RMB 600 million to R&D.
Achieve “dual‑engine” growth by leveraging the company’s cutting-edge CRO platform and its proprietary innovative drug pipeline.
Patent Information
The total number of existing invention patents is 137, including 14 PCT applications; there are 21 platform patents and 113 pipeline patents.
A total of 64 invention patents have been granted, including PICT patents that have been authorized in China, the United States, Europe, Canada, Japan, Australia, and other countries.
|
Status of Zhongsheng Whole Peptide Invention Patent (Unit: Piece) |
||||||
|
Quantity |
Number of Authorizations |
In the trial |
Withdrawal |
PCT |
domestic patent |
|
|
Total number of patents |
25 |
8 |
15 |
2 |
4 |
21 |
|
Platform Patent |
11 |
4 |
7 |
0 |
2 |
9 |
|
Pipeline Project |
13 |
4 |
8 |
1 |
1 |
12 |
|
Other |
1 |
0 |
0 |
1 |
1 |
0 |
Empowering the thriving development of peptide therapeutics worldwide, enabling cost‑effective access to peptide medicines for patients around the globe, and contributing to human health.
Hunan Zhongsheng Quanpeptide Biotechnology Co., Ltd.
Contact Information
Email:info@peplib.com
Company Address: Building 5, Modern Service Industry Headquarters Park, No. 1769 Yunlong Avenue, Yunlong Demonstration Zone, Zhuzhou, Hunan Province
Copyright © 2023 Hunan Zhongsheng Quanpeptide Biotechnology Co., Ltd. This website supports IPv6.